Associate member, H Lee Moffitt Cancer Center
Hematology
Dr. Rachid C. Baz, MD
|
|
Give Review
Rachid C. Baz is an expert in the field of Hematology. Rachid C. Baz is a published doctor and has 45 publications published. The lastest was: 'A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.' He accepts all Medicare patients.
Publications
- A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
- Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.
- Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain Amyloidosis without a hematologic response.
- An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
- Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients.
- Phase I Trial of Bortezomib and "Non-Hybrid "(Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.
- Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and/or refractory multiple myeloma.
- Inhibition of CRM1-dependent nuclear export sensitizes malignant Cells to cytotoxic and targeted agents.
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
- A preclinical assay for chemosensitivity in multiple myeloma.
- Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, Vincristine, Dexamethasone, and Lenalidomide combination therapy followed by lenalidomide mainte...
- Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
- Sequence of novel agents in multiple myeloma: An instrumental variable Analysis.
- Allogeneic hematopoietic Cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
- Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: a Focus on Hematopoietic Cell Transplantation.
- Human immunodeficiency virus (HIV)-negative plasmablastic Lymphoma: a single institutional experience and literature review.
- Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation.
- Clinical factors associated with outcome in patients with metastatic clear-Cell renal Cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
- Phase II study of lenalidomide in patients with metastatic renal Cell carcinoma.
- Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
- Lenalidomide mode of action: linking bench and clinical findings.
- Merkel cell carcinoma in the peripheral blood of a patient with concomitant chronic lymphocytic Leukemia and multiple myeloma.
- Acquisition of resistance towards HYD1 correlates with a reduction in cleaved alpha 4 integrin expression and a compromised CAM-DR phenotype.
- Lenalidomide: the emerging role of a novel targeted agent in Malignancies.
- Does low-dose aspirin have antineoplastic effects in multiple myeloma?
- G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma Cells.
- Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.
- Prevalence of vitamin B12 deficiency in patients with plasma Cell dyscrasias: a retrospective review.
- Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed Acute myeloid leuke...
- Impact of remission induction chemotherapy on survival in older adults with Acute myeloid leukemia.
- Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma Cell myeloma treated with a thalidomide-based regimen.
- Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
- The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
- Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple m...
- Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
- Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma.
- Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Expe...
- Prognostic factors associated with long-term survival in previously untreated metastatic renal Cell carcinoma.
- Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
- Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
- The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.
- Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective Analysis.
- An association between renal Cell carcinoma and multiple myeloma: a case series and clinical implications.
Schools
American University Of Beirut
Cleveland Clinic FoundationInternal Medicine
Cleveland Clinic FoundationHematology and Medical Oncology
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Amyloidosis
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Education
-
Cleveland Clinic Foundation -
American University of Beirut Faculty of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1831393875 | |
| NPPES Provider LastName | BAZ | |
| NPPES Provider FirstName | RACHID | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 685.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 94.0 | |
| Percent Opioid Claims | 13.72 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831393875 |
| Last Name Of The Provider | BAZ |
| First Name Of The Provider | RACHID |
| View All |
Similar Doctors
|
Dr. Jinming Song, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Yasir Alhassani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lubomir Sokol, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jose L. Ochoa-Bayona, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Scott J. Antonia, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Joseph Pidala, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Teresa L. Field, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Asmita Mishra, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mohamed A. Kharfan Dabaja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adil Daud, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lia E. Perez, MD
This Doctor is OpenDoctor Recommended.
|